NGNE

Neurogene

• Dow Jones·08/12 16:02

  Neurogene Price Target Cut to $166.00/Share From $180.00 by Canaccord Genuity

• Dow Jones·08/12 16:02

  Neurogene Is Maintained at Buy by Canaccord Genuity

• Benzinga·08/12 15:53

  Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166

• Dow Jones·08/12 12:40

  Neurogene Price Target Raised to $81.00/Share From $69.00 by Guggenheim

• Dow Jones·08/12 12:40

  Neurogene Is Maintained at Buy by Guggenheim

• Benzinga·08/12 12:31

  Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81

• Dow Jones·08/12 11:50

  Neurogene Price Target Cut to $65.00/Share From $70.00 by HC Wainwright & Co.

• Dow Jones·08/12 11:50

  Neurogene Is Maintained at Buy by HC Wainwright & Co.

• Benzinga·08/12 11:40

  HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65

• TipRanks·08/12 11:25

  Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166

• TipRanks·08/12 11:16

  Guggenheim Sticks to Their Buy Rating for Neurogene (NGNE)

• TipRanks·08/12 10:35

  Neurogene Buy Rating Reaffirmed as NGN-401 Progresses; 12‑Month Price Target Trimmed from $70 to $65 on Model Updates and Financing Dilution

• TipRanks·08/12 05:30

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• TipRanks·08/11 23:20

  Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

• TipRanks·08/11 17:35

  Analyst Maintains Buy on NGN-401 After Strong Rett Data and Cleared Safety Window, Trims Price Target to $63